Hormones are deeply entangled with postural orthostatic tachycardia syndrome, influencing who develops POTS, when symptoms flare, and how severe they become. The condition strikes women of reproductive age far more often than men, and symptoms frequently shift with menstrual cycles, pregnancy, and menopause. But the hormonal story extends well beyond sex hormones: aldosterone, norepinephrine, cortisol, growth hormone, and even melatonin all play roles in the dysfunction that defines POTS.
Why POTS Overwhelmingly Affects Women
Roughly nine out of every ten people diagnosed with POTS are female, and the typical patient is a woman in her late twenties or early thirties. A 2025 study of 500 POTS patients found that women carried a heavier symptom burden than men, scoring higher on a standardized measure of autonomic symptoms and reporting worse overall quality of life. Women also waited far longer for a diagnosis, averaging about seven years compared to roughly four years for men, and were nearly three times as likely to spend a decade or more undiagnosed. Two-thirds of the women in that study said their symptoms had been attributed to anxiety before they received a POTS diagnosis, compared to about half of the men.
1European Journal of Cardiovascular Nursing. Biological sex-dependent differences in postural orthostatic tachycardia syndrome – Section: ResultsThe reason for this sex disparity likely traces to physiology rather than a single hormone. After accounting for body size, women tend to have lower stroke volume and lower total blood volume than men. While standing, women also show reduced venous return from less effective respiratory and skeletal muscle pumping, weaker sympathetic nerve-to-blood-vessel signaling, and greater capacity for blood vessels to dilate.
2Autonomic Neuroscience. Women, orthostatic tolerance, and POTS: a narrative reviewThese baseline differences mean women have less circulatory reserve when gravity pulls blood toward the legs upon standing. That smaller margin makes them more vulnerable to the runaway heart-rate response that defines POTS.
Menstrual Cycle Fluctuations
If you have POTS and feel noticeably worse at certain times of the month, you are far from alone. A large cross-sectional survey found that up to about 72% of women with POTS reported their symptoms shifted during their menstrual cycle. The worst stretches tended to fall just before menstruation or during menses itself, while symptoms eased during the early or late post-menstrual phase.
3PubMed Central. The Long-Term Postural Orthostatic Tachycardia Syndrome Outcomes Survey-Gynecologic Findings: A Cross-Sectional Survey in Young Women – Section: ResultsThe mechanism likely involves progesterone and estrogen’s effects on blood vessels and fluid balance. Progesterone rises sharply after ovulation and peaks in the luteal phase (the roughly two weeks before menstruation). Among its many effects, progesterone relaxes smooth muscle in vein walls, which can promote blood pooling in the lower body. Estrogen similarly dilates blood vessels. When both hormones drop just before menstruation, the abrupt shift in vascular tone, combined with premenstrual fluid retention and then fluid loss, may destabilize an already fragile circulatory system.
This cyclical pattern has practical implications. Tracking symptoms against your cycle can help you and your physician identify a hormonal component. Some clinicians adjust fluid and salt intake recommendations around the premenstrual window, or time medication changes to coincide with the expected flare.
The Renin-Aldosterone Paradox
One of the most striking hormonal findings in POTS involves aldosterone, the hormone that tells your kidneys to retain sodium and water. People with POTS tend to have measurably lower blood volume than healthy people. Under normal circumstances, low blood volume should trigger the renin-angiotensin-aldosterone system (RAAS) to kick into gear, ramping up aldosterone production to hold onto fluid and bring volume back up. In many POTS patients, that compensatory response is broken.
A study comparing POTS patients with healthy controls found that despite substantially lower plasma volume in the POTS group (a deficit averaging about 334 mL more than controls), plasma renin activity was identical between the two groups. Aldosterone levels were actually lower in the POTS patients, roughly half that of controls.
4PubMed. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome – Section: METHODS AND RESULTSThis “renin-aldosterone paradox” means the body is running low on blood volume but the hormonal alarm system that should be correcting the problem stays quiet. The resulting chronic volume deficit worsens the drop in blood pressure upon standing, forcing the heart to beat faster to compensate.
Further research has added another layer. Some POTS patients show elevated levels of angiotensin II, a hormone that normally constricts blood vessels and stimulates aldosterone release, yet their aldosterone remains inappropriately low. This suggests reduced adrenal responsiveness and possibly abnormal activity of the enzyme ACE2, which degrades angiotensin II.
5Heart Rhythm. Abnormal of angiotensin regulation in postural tachycardia syndrome – Section: ConclusionThis disconnect between angiotensin levels and aldosterone output points to a specific hormonal bottleneck, not just a general autonomic malfunction. It also explains why salt loading and volume expansion strategies help some POTS patients more than others: those with the most dysfunctional RAAS stand to gain the most from externally supplementing what their hormones are failing to regulate.
Norepinephrine and the Hyperadrenergic Subtype
Norepinephrine is both a hormone and a neurotransmitter, and it occupies a central role in one of the recognized POTS subtypes. In “hyperadrenergic” POTS, standing triggers an outsized release of norepinephrine, producing a surge in heart rate, tremor, anxiety, and sometimes a paradoxical rise in blood pressure. Research in children and adolescents with POTS found that higher orthostatic norepinephrine levels correlated with more severe symptoms and with a larger heart-rate jump during tilt-table testing.
6PubMed Central. Orthostatic plasma norepinephrine level as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome – Section: DiscussionThe norepinephrine excess in hyperadrenergic POTS appears to result from impaired baroreflex control. Normally, when blood pressure drops on standing, the baroreflexes trigger just enough sympathetic nervous system activity to constrict blood vessels and stabilize circulation. In some POTS patients, that finely tuned response overshoots, flooding the bloodstream with norepinephrine that speeds the heart without adequately constricting the veins where blood is pooling. Clinically, this finding is useful because orthostatic norepinephrine levels can help predict whether beta-blockers, which blunt the effects of norepinephrine on the heart, will be an effective treatment for a given patient.
Cortisol and the Stress-Hormone Connection
Cortisol, the body’s primary stress hormone, also appears dysregulated in POTS. A study comparing cortisol levels across three groups found that POTS patients had cortisol levels roughly twice as high as healthy controls. Interestingly, people with vasovagal syncope (fainting spells) showed a similarly elevated cortisol pattern.
7PubMed Central. Comparison of cortisol levels in patients with vasovagal syncope and postural tachycardia syndrome – Section: ResultsWhether elevated cortisol is a cause of POTS symptoms, a consequence of the constant physiological stress the condition imposes, or both, remains an open question. Chronically high cortisol can impair immune function, disturb sleep, promote fluid retention in some tissues while depleting it in others, and worsen anxiety, all of which overlap with the symptom profile many POTS patients report. The finding does help explain why POTS can feel so physically exhausting: the body appears locked in a state of stress-hormone overdrive, even during rest.
Pregnancy and POTS
Pregnancy rearranges nearly every hormonal system in the body, and for women with POTS the effects are surprisingly variable. The first trimester, when blood volume has not yet expanded substantially but progesterone is already rising and dilating blood vessels, often brings a worsening of symptoms. By the second trimester, the dramatic increase in blood and plasma volume that pregnancy demands tends to improve POTS symptoms, sometimes significantly. The third trimester is a mixed bag, with some women maintaining that improvement and others experiencing a return of symptoms as the growing uterus compresses veins and impedes blood return to the heart.
8PubMed Central. POTS and Pregnancy: A Review of Literature and Recommendations for Evaluation and Treatment – Section: ResultsOverall, studies report that roughly 60 to 68% of pregnant women with POTS experience stable or improved symptoms, while 30 to 40% get worse. Women who had severe POTS or were on medications at the time of conception were more likely to decline, while those with milder symptoms tended to do better. The postpartum period introduces yet another hormonal upheaval: about half of women reported feeling the same or better than before pregnancy, while the other half felt worse. Breastfeeding may offer some protective effect, as women who were still nursing tended to report more stable symptoms.
8PubMed Central. POTS and Pregnancy: A Review of Literature and Recommendations for Evaluation and Treatment – Section: ResultsThese findings reinforce how central blood volume is to POTS. Pregnancy is essentially a natural experiment in volume expansion, and the periods when volume rises most dramatically (mid-pregnancy) align with symptom improvement, while the periods of hormonal upheaval without volume support (early pregnancy, postpartum) align with flares.
Puberty as a Trigger
Many POTS patients trace their first symptoms to adolescence, and there is reason to think puberty itself is involved. POTS in children and teenagers has been observed to begin after growth spurts or after the onset of menstruation. Reports also exist of symptoms improving with testosterone administration, which further implicates sex hormones in the onset or perpetuation of the condition.
9Pediatrics. Pediatric Postural Orthostatic Tachycardia Syndrome: Where We Stand – Section: Risk Factors and OutcomesThe logic here is straightforward. Puberty brings rapid changes in body size, vascular compliance, and hormonal milieu. A teenager who has just grown several inches may have longer blood vessels but not yet enough blood volume to fill them adequately. Rising estrogen levels in girls increase vascular dilation. The autonomic nervous system is also still maturing. All of these shifts create a window of vulnerability that can unmask POTS in someone whose circulatory system is already on the edge. The good news is that many adolescents with POTS improve over time as their bodies catch up to these changes. Estimates vary, but a meaningful proportion of teenagers diagnosed with POTS see substantial improvement or resolution within a few years.
Menopause and Hormone Replacement Therapy
If puberty and menstrual cycles affect POTS, the loss of ovarian hormones at menopause raises obvious questions. Unfortunately, the research here is thin. No rigorous studies have directly examined how menopause changes POTS outcomes or whether hormone replacement therapy helps or harms POTS patients. The topic is newly recognized as a significant gap in the literature, particularly because the generation of women diagnosed with POTS in their twenties and thirties is now aging into perimenopause.
10PubMed Central. Postural Orthostatic Tachycardia Syndrome, Menopause and Hormone Replacement Therapy: Clinical Decisions in Times of UncertaintyWhat experts have offered so far is cautious guidance. For women experiencing significant menopausal symptoms alongside a worsening of POTS during perimenopause or postmenopause, certain forms of hormone replacement may be considered on a case-by-case basis. Vaginal estrogen appears safe for most women. Transdermal estrogen patches and micronized progesterone can be used for substantial menopausal symptoms, though the long-term effects in the POTS population remain unknown. The recommendation is to account for cardiovascular risk, comorbidities, and individual symptom patterns rather than to follow a one-size-fits-all protocol.
10PubMed Central. Postural Orthostatic Tachycardia Syndrome, Menopause and Hormone Replacement Therapy: Clinical Decisions in Times of UncertaintyThis is one of those frustrating areas where the science genuinely has not caught up with the clinical need. Women with POTS who are approaching menopause should expect to have frank conversations with their physicians about trial-and-error approaches rather than evidence-based certainty.
Thyroid Autoimmunity and POTS
Hashimoto’s thyroiditis, the most common cause of underactive thyroid, shows up more often in POTS patients than in the general population. The connection is not that thyroid hormone directly causes POTS, but rather that autoimmune thyroid disease and POTS may share underlying immune mechanisms. POTS frequently coexists with other autoimmune conditions, and the presence of Hashimoto’s strengthens the broader hypothesis that immune-mediated damage to autonomic nerves or receptors contributes to the syndrome in a subset of patients.
11PubMed Central. Understating the correlation between Postural Orthostatic Tachycardia Syndrome (POTS) and Hashimoto’s Thyroiditis – Section: AbstractFrom a practical standpoint, thyroid dysfunction can worsen tachycardia and fatigue independently of POTS, so getting thyroid levels properly managed may reduce some of the symptom burden even though it won’t cure the underlying autonomic dysfunction. POTS patients who have not had thyroid function tested are missing a potentially treatable contributor.
Growth Hormone
A less well-known hormonal finding involves growth hormone (GH). A study measuring circulating GH levels found that POTS patients had significantly lower levels than healthy controls, with median GH roughly a quarter of the control value. Lower GH also correlated with worse autonomic symptoms among the POTS group.
12PubMed Central. Circulating levels of growth hormone in postural orthostatic tachycardia syndrome – Section: ResultsGrowth hormone influences vascular tone, fluid retention, and cardiac function, so low levels could plausibly contribute to the hemodynamic instability that characterizes POTS. The relationship between GH and blood pressure in this study was notable: lower GH was associated with higher resting systolic blood pressure, though GH levels did not relate to heart rate itself. Whether low GH is a cause, a consequence, or simply a bystander in POTS remains to be worked out, and no one has yet tested whether GH supplementation helps.
Melatonin and Heart Rate
Melatonin is best known as a sleep hormone, but it also affects blood vessel tone and heart rate. A randomized crossover trial tested whether oral melatonin could reduce the standing tachycardia that defines POTS. It did, modestly. Standing heart rate dropped more after melatonin than after placebo, and the effect was statistically significant at two and four hours after dosing. Seated heart rate also improved at two and three hours.
13PubMed Central. Melatonin reduces tachycardia in Postural Tachycardia Syndrome (POTS): A Randomized, Crossover Trial – Section: RESULTSThe effect was not dramatic, but for a hormone supplement with a mild side-effect profile, any reduction in standing tachycardia is noteworthy. Melatonin constricts blood vessels mildly, which may counteract the excessive venous pooling that drives the heart-rate spike. This finding also hints that circadian rhythms could shape POTS symptom severity throughout the day. Many patients report feeling worse in the morning, a period when melatonin levels are falling, cortisol is spiking, and blood volume is at its lowest after overnight fluid redistribution and dehydration. The hormonal shifts of waking up are, in a sense, a mini-challenge to the same systems that POTS disrupts on a larger scale.
Why No Single Hormone Explains POTS
The breadth of hormonal involvement in POTS can feel overwhelming, but it also reflects a real feature of the condition: POTS is not one disease with one cause. It is a syndrome, a collection of symptoms unified by an excessive heart-rate rise on standing, which can be driven by low blood volume, excessive sympathetic activation, venous pooling, autoimmune nerve damage, or some combination. Different hormonal abnormalities map onto these different mechanisms. The renin-aldosterone paradox matters most for patients whose core problem is low blood volume. Norepinephrine excess matters most in the hyperadrenergic subtype. Estrogen and progesterone fluctuations matter most for women whose symptoms cycle with menstruation. Thyroid autoimmunity and cortisol may matter most in patients whose POTS is driven by immune dysfunction or chronic physiological stress.
This is also why POTS treatment tends to be individualized. A patient whose labs show low aldosterone and low blood volume may benefit most from fludrocortisone (a synthetic aldosterone) and aggressive fluid intake. A patient with sky-high standing norepinephrine may respond better to a beta-blocker. A patient whose symptoms reliably flare premenstrually might benefit from cycle-aware adjustments. Understanding which hormonal systems are off in your particular case can sharpen the treatment strategy rather than leaving you cycling through generic approaches.